Table 1.

AHRO HDRB boost patients' characteristics including number of patients (no. of patients), HDRB physical, and biological prescription dose (respectively, Brachytherapy Prescription dose-physical and equivalent), toxicity rate, mean, and median time to stricture (%), patient who had received Neo-Adjuvant Androgen Deprivation and age.

	Group 1	Group 2	Group 3	Group 4	Total
No of patients	131	117	8	2	258
Brachytherapy Prescription dose (physical dose, Gy)	18 Gy in 3 fractions	19 Gy in 2 fractions	17 Gy in 2 fractions	10 and 6 Gy in 2 fractions
External Beam Prescription dose (physical dose, Gy)	46 Gy in 23 fractions	46 Gy in 23 fractions	46 Gy in 23 fractions	46 Gy in 23 fractions
Brachytherapy Prescription dose (2 Gy equivalent dose, α/β = 5 Gy)	28.3 Gy	39.4 Gy	32.8 Gy	30.8 Gy
Total dose EBRT + HDRB (2 Gy equivalent dose, α/β = 5 Gy)	74.3 Gy	85.4 Gy	78.8 Gy	76.8 Gy
Toxicity rate at 4 years (%)	6.9%	20.5%	0%	0%	12.8%
Mean time to stricture (years)	3.6	2.1	Not applicable	Not applicable
Median time to stricture (years)	3.0	1.4	Not applicable	Not applicable
Adjuvant androgen deprivation (no of patients)	118	113	8	2	241
Mean age (years)	65.4	66.3	66.1	65	65.7

For EBRT the 46 in 2 Gy per fraction prescription is shown as only 1 patient in the whole cohort had 50 in 2 Gy per fraction.